Table 1.

Demographics at study baseline

Docetaxel/prednisone/custirsenMitoxantrone/prednisone/custirsenTotal population
(n = 20)(n = 22)(N = 42)
Median age, y, range68 (48–80)61 (49–81)66 (48–81)
Median PSA, ng/mL, range154 (5–3570)116 (20–2776)130 (5–3570)
PSA ≥20 ng/mL (%)9010095
Median hemoglobin, g/dL, range12.3 (9.0–13.7)12.6 (8.5–14.3)12.3 (8.5–14.3)
Median LDH, U/L, range231 (157–596)291 (142–1088)270 (142–1088)
Karnofsky score (% of patients)70%–80%: (35)70%–80%: (41)70%–80%: (38)
90%–100%: (65)90%–100%: (59)90%–100%: (62)
Receiving bisphosphonates (%)403638
Radiotherapy since progression (%)504548
Worst pain score ≥2 at study entry (%)405548
On opioids at study entry (%)454143
Sites of disease (% of patients)
 Bone1009698
 Node655057
 Visceral202724
Measurable disease (% of patients)655057
Median time (mo) from end of first-line docetaxel therapy to study treatment (range)4.9 (0.9–7)3.9 (0.6–11)4.2 (0.6–11)
  • Abbreviation: LDH, lactic dehydrogenase.